Monte Rosa Therapeutics, Inc. (GLUE)

Market Cap	219.53M
Revenue (ttm)	1.06M
Net Income (ttm)	-135.28M
Shares Out	61.15M
EPS (ttm)	-2.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	290,610
Open	3.960
Previous Close	3.940
Day's Range	3.540 - 4.150
52-Week Range	2.440 - 8.840
Beta	1.41
Analysts	Buy
Price Target	12.25 (+241.23%)
Earnings Date	Aug 8, 2024

About GLUE

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 24, 2021
• Employees: 130
• Stock Exchange: NASDAQ
• Ticker Symbol: GLUE

Analyst Forecast

According to 4 analysts, the average rating for GLUE stock is "Buy." The 12-month stock price forecast is $12.25, which is an increase of 241.23% from the latest price.

Price Target

$12.25

(241.23% upside)

Analyst Consensus: Buy